tiprankstipranks
Johnson & Johnson (JNJ)
NYSE:JNJ
US Market
JNJ
Johnson & Johnson
RESEARCH TOOLSreports
Want to see JNJ full AI Analyst Report?

Johnson & Johnson (JNJ) Stock Forecast & Price Target

27,978 Followers
See the Price Targets and Ratings of:

JNJ Analyst Ratings

Moderate Buy
17Ratings
Moderate Buy
11 Buy
6 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Johnson
& Johnson
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JNJ Stock 12 Month Forecast

Average Price Target

$264.73
▲(13.05% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $264.73 with a high forecast of $285.00 and a low forecast of $240.00. The average price target represents a 13.05% change from the last price of $234.18.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"148":"$148","217":"$217","286":"$286","182.5":"$182.5","251.5":"$251.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":285,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$285.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":264.7333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$264.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$240.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[148,182.5,217,251.5,286],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,244.12,247.26461538461538,250.40923076923076,253.55384615384617,256.6984615384615,259.8430769230769,262.9876923076923,266.1323076923077,269.2769230769231,272.4215384615385,275.56615384615384,278.71076923076924,281.8553846153846,{"y":285,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,244.12,245.70564102564103,247.29128205128205,248.87692307692308,250.4625641025641,252.04820512820513,253.63384615384615,255.21948717948715,256.8051282051282,258.3907692307692,259.97641025641025,261.56205128205124,263.1476923076923,{"y":264.7333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,244.12,243.80307692307693,243.48615384615385,243.16923076923078,242.8523076923077,242.53538461538463,242.21846153846155,241.90153846153845,241.58461538461538,241.2676923076923,240.95076923076923,240.63384615384615,240.31692307692308,{"y":240,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":149.095,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.273,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.483,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.993,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.189,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.121,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.898,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.685,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.254,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.855,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":229.529,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248.56,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$285.00Average Price Target$264.73Lowest Price Target$240.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on JNJ
Joanne Wuensch
Citi
Citi
$285
Buy
21.70%
Upside
Reiterated
04/26/26
Citi Reaffirms Their Buy Rating on Johnson & Johnson (JNJ)
TD Cowen Analyst forecast on JNJ
Josh Jennings
TD Cowen
TD Cowen
$250
Buy
6.76%
Upside
Reiterated
04/23/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Eli Lilly & Co (NYSE: LLY)
Guggenheim Analyst forecast on JNJ
Vamil Divan
Guggenheim
Guggenheim
$244→$266
Buy
13.59%
Upside
Reiterated
04/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Barclays Analyst forecast on JNJ
Matt Miksic
Barclays
Barclays
$234→$255
Hold
8.89%
Upside
Assigned
04/16/26
Analysts Conflicted on These Healthcare Names: Johnson & Johnson (NYSE: JNJ), BeOne Medicines (NASDAQ: ONC) and Helus Pharma (NASDAQ: HELP)
Bank of America Securities Analyst forecast on JNJ
Jason Gerberry
Bank of America Securities
Bank of America Securities
$253→$254
Hold
8.46%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Morgan Stanley Analyst forecast on JNJ
Terence Flynn
Morgan Stanley
Morgan Stanley
$267→$283
Buy
20.85%
Upside
Assigned
04/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Goldman Sachs Analyst forecast on JNJ
Asad Haider
Goldman Sachs
Goldman Sachs
$265→$275
Buy
17.43%
Upside
Reiterated
04/15/26
Goldman Sachs Reaffirms Their Buy Rating on Johnson & Johnson (JNJ)
J.P. Morgan Analyst forecast on JNJ
Chris Schott
J.P. Morgan
J.P. Morgan
$250→$260
Hold
11.03%
Upside
Reiterated
04/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Zealand Pharma (Other OTC: ZLDPF) and Camurus AB (Other OTC: CAMRF)
Wells Fargo Analyst forecast on JNJ
Larry Biegelsen
Wells Fargo
Wells Fargo
$240→$263
Buy
12.31%
Upside
Assigned
04/15/26
Johnson & Johnson (JNJ) Gets a Buy from Wells Fargo
Stifel Nicolaus Analyst forecast on JNJ
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$220→$250
Hold
6.76%
Upside
Assigned
04/15/26
Johnson & Johnson price target raised to $250 from $220 at StifelJohnson & Johnson price target raised to $250 from $220 at Stifel
RBC Capital Analyst forecast on JNJ
Shagun Singh Chadha
RBC Capital
RBC Capital
$255→$265
Buy
13.16%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), Telix Pharmaceuticals (Other OTC: TLPPF) and Johnson & Johnson (NYSE: JNJ)
Bernstein Analyst forecast on JNJ
Lee Hambright
Bernstein
Bernstein
―
Hold
―
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (NYSE: LH), Recursion Pharmaceuticals (NASDAQ: RXRX) and Johnson & Johnson (NYSE: JNJ)
Erste Group Analyst forecast on JNJ
Hans Engel
Erste Group
Erste Group
―
Buy
―
Reiterated
04/02/26
Erste Group Remains a Buy on Johnson & Johnson (JNJ)
Scotiabank Analyst forecast on JNJ
Louise Chen
Scotiabank
Scotiabank
$265
Buy
13.16%
Upside
Reiterated
03/19/26
Analysts Are Bullish on These Healthcare Stocks: Immuneering (IMRX), Johnson & Johnson (JNJ)
UBS Analyst forecast on JNJ
Danielle Antalffy
UBS
UBS
$245→$280
Buy
19.57%
Upside
Assigned
03/17/26
Johnson & Johnson price target raised to $280 from $245 at UBSJohnson & Johnson price target raised to $280 from $245 at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on JNJ
Joanne Wuensch
Citi
Citi
$285
Buy
21.70%
Upside
Reiterated
04/26/26
Citi Reaffirms Their Buy Rating on Johnson & Johnson (JNJ)
TD Cowen Analyst forecast on JNJ
Josh Jennings
TD Cowen
TD Cowen
$250
Buy
6.76%
Upside
Reiterated
04/23/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Eli Lilly & Co (NYSE: LLY)
Guggenheim Analyst forecast on JNJ
Vamil Divan
Guggenheim
Guggenheim
$244→$266
Buy
13.59%
Upside
Reiterated
04/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Barclays Analyst forecast on JNJ
Matt Miksic
Barclays
Barclays
$234→$255
Hold
8.89%
Upside
Assigned
04/16/26
Analysts Conflicted on These Healthcare Names: Johnson & Johnson (NYSE: JNJ), BeOne Medicines (NASDAQ: ONC) and Helus Pharma (NASDAQ: HELP)
Bank of America Securities Analyst forecast on JNJ
Jason Gerberry
Bank of America Securities
Bank of America Securities
$253→$254
Hold
8.46%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Morgan Stanley Analyst forecast on JNJ
Terence Flynn
Morgan Stanley
Morgan Stanley
$267→$283
Buy
20.85%
Upside
Assigned
04/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Goldman Sachs Analyst forecast on JNJ
Asad Haider
Goldman Sachs
Goldman Sachs
$265→$275
Buy
17.43%
Upside
Reiterated
04/15/26
Goldman Sachs Reaffirms Their Buy Rating on Johnson & Johnson (JNJ)
J.P. Morgan Analyst forecast on JNJ
Chris Schott
J.P. Morgan
J.P. Morgan
$250→$260
Hold
11.03%
Upside
Reiterated
04/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Zealand Pharma (Other OTC: ZLDPF) and Camurus AB (Other OTC: CAMRF)
Wells Fargo Analyst forecast on JNJ
Larry Biegelsen
Wells Fargo
Wells Fargo
$240→$263
Buy
12.31%
Upside
Assigned
04/15/26
Johnson & Johnson (JNJ) Gets a Buy from Wells Fargo
Stifel Nicolaus Analyst forecast on JNJ
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$220→$250
Hold
6.76%
Upside
Assigned
04/15/26
Johnson & Johnson price target raised to $250 from $220 at StifelJohnson & Johnson price target raised to $250 from $220 at Stifel
RBC Capital Analyst forecast on JNJ
Shagun Singh Chadha
RBC Capital
RBC Capital
$255→$265
Buy
13.16%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), Telix Pharmaceuticals (Other OTC: TLPPF) and Johnson & Johnson (NYSE: JNJ)
Bernstein Analyst forecast on JNJ
Lee Hambright
Bernstein
Bernstein
―
Hold
―
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (NYSE: LH), Recursion Pharmaceuticals (NASDAQ: RXRX) and Johnson & Johnson (NYSE: JNJ)
Erste Group Analyst forecast on JNJ
Hans Engel
Erste Group
Erste Group
―
Buy
―
Reiterated
04/02/26
Erste Group Remains a Buy on Johnson & Johnson (JNJ)
Scotiabank Analyst forecast on JNJ
Louise Chen
Scotiabank
Scotiabank
$265
Buy
13.16%
Upside
Reiterated
03/19/26
Analysts Are Bullish on These Healthcare Stocks: Immuneering (IMRX), Johnson & Johnson (JNJ)
UBS Analyst forecast on JNJ
Danielle Antalffy
UBS
UBS
$245→$280
Buy
19.57%
Upside
Assigned
03/17/26
Johnson & Johnson price target raised to $280 from $245 at UBSJohnson & Johnson price target raised to $280 from $245 at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Johnson & Johnson

3 Months
xxx
Success Rate
23/27 ratings generated profit
85%
Average Return
+4.70%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 85.19% of your transactions generating a profit, with an average return of +4.70% per trade.
1 Year
Danielle AntalffyUBS
Success Rate
26/27 ratings generated profit
96%
Average Return
+12.54%
Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 96.30% of your transactions generating a profit, with an average return of +12.54% per trade.
2 Years
xxx
Success Rate
39/43 ratings generated profit
91%
Average Return
+20.14%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 90.70% of your transactions generating a profit, with an average return of +20.14% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JNJ Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
34
27
25
24
23
Hold
19
18
17
14
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
53
45
42
38
35
In the current month, JNJ has received 23 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. JNJ average Analyst price target in the past 3 months is 264.73.
Each month's total comprises the sum of three months' worth of ratings.

JNJ Financial Forecast

JNJ Earnings Forecast

Next quarter’s earnings estimate for JNJ is $2.84 with a range of $2.65 to $3.00. The previous quarter’s EPS was $2.70. JNJ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.
Next quarter’s earnings estimate for JNJ is $2.84 with a range of $2.65 to $3.00. The previous quarter’s EPS was $2.70. JNJ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.

JNJ Sales Forecast

Next quarter’s sales forecast for JNJ is $24.96B with a range of $23.97B to $25.36B. The previous quarter’s sales results were $24.07B. JNJ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.
Next quarter’s sales forecast for JNJ is $24.96B with a range of $23.97B to $25.36B. The previous quarter’s sales results were $24.07B. JNJ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.

JNJ Stock Forecast FAQ

What is JNJ’s average 12-month price target, according to analysts?
Based on analyst ratings, Johnson & Johnson’s 12-month average price target is 264.73.
    What is JNJ’s upside potential, based on the analysts’ average price target?
    Johnson & Johnson has 13.05% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is JNJ a Buy, Sell or Hold?
          Johnson & Johnson has a consensus rating of Moderate Buy which is based on 11 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Johnson & Johnson’s price target?
            The average price target for Johnson & Johnson is 264.73. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $285.00 ,the lowest forecast is $240.00. The average price target represents 13.05% Increase from the current price of $234.18.
              What do analysts say about Johnson & Johnson?
              Johnson & Johnson’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of JNJ?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.